Marlborough-based Sunovion Pharmaceuticals has extended a drug discovery and development agreement with a New York company.
Sunovion and PGI Drug Discovery LLC (PsychoGenics) will continue the agreement that was first started in 2007 for another four years, PsychoGenics announced in a release Monday. The agreement allows the companies to screen their combined compound libraries for new treatments for neuropsychiatric disorders. The collaboration has led to the identification of potential drug candidates including a compound in clinical development, according to PsychoGenics.
PsychoGenics specializes in using its proprietary technology to discover new drug applications.
